Buy ARA-290 Online
ARA-290, also known as cibinetide, is an 11-amino-acid peptide engineered from erythropoietin (EPO) to activate tissue-protective pathways without stimulating red blood cell production. It has attracted considerable interest because research has connected it with nerve repair, metabolic control, inflammation, and tissue protection.
Unlike many experimental peptides, ARA-290 has progressed through multiple Phase 2 human studies.
Product Information
ARA-290 was designed around the tissue-protective portion of EPO while avoiding EPO’s erythropoietic activity. Research suggests that it interacts with the innate repair receptor (IRR) and can influence pathways involved in tissue protection, inflammation, and nerve regeneration.
Clinical research has investigated ARA-290 in sarcoidosis-associated small-fiber neuropathy, type 2 diabetes with neuropathic symptoms, and diabetic macular edema.
How Does ARA-290 Work?
ARA-290 activates the innate repair receptor, promoting signaling associated with tissue protection, reduced inflammatory activity, and nerve repair without directly stimulating erythropoiesis.
ARA-290 Benefits
Supports Nerve-Repair Research
ARA-290 has produced some of its strongest clinical signals in small-fiber neuropathy research. Trials in sarcoidosis-associated neuropathy reported improvements in neuropathy scores alongside increases in corneal nerve-fiber density.
Supports Tissue Protection
The peptide was specifically engineered to activate protective EPO-related pathways without the red-blood-cell stimulation associated with full EPO. This makes it particularly interesting in research involving tissue injury, inflammation, and cellular repair.
Metabolic Research
A Phase 2 study in people with type 2 diabetes found that 4 mg/day of ARA-290 was associated with improvements in HbA1c and lipid measures, alongside improvements in neuropathic symptoms.
Neuroinflammation and Nerve Regeneration
ARA-290 research extends beyond symptom relief. Studies have investigated changes in corneal nerve-fiber density and sensory function, supporting continued interest in its potential role in nerve-regeneration research.
ARA-290 Side Effects
Clinical trials have generally reported good tolerability, with no consistent injection-site irritation or major drug-related adverse-effect pattern. Some clinical studies did record individual events including headache, gastrointestinal symptoms, and other nonspecific complaints, although investigators generally did not consider them clearly attributable to ARA-290.
ARA-290 Dosage
Human clinical studies have most commonly investigated 4 mg subcutaneously once daily for 28 days. Earlier research also used 2 mg intravenously three times weekly, while dose-ranging work examined 1, 4 and 8 mg/day.
Research References
Brines M, et al. ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Mol Med. 2014. PMID: 25387363.
PubMed — ARA-290 Clinical Trial
Brines M, et al. ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density.
PubMed — ARA-290 Neuropathy Research
Purerawz Disclaimer
Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an independent information and affiliate platform. Where available, links may direct readers to independent third-party providers, and Purerawz may receive a commission from qualifying purchases at no additional cost to the reader.
The information provided is for educational and informational purposes only. Dosage figures may reflect published research protocols, clinical trial doses, or reported community use and should not be interpreted as personalized medical instructions. Research findings, particularly those from animal studies or small early-stage human trials, do not necessarily establish that a product is safe or effective for every individual or condition.
